From the ongoing Bill Ackman-Valeant saga to Stada's impending sale to a flurry of potential billion-dollar divestments, big pharmaceutical news has been a big deal of late. As these stories play out, a pair of other deals involving major names in the industry have also been announced.
First, PTC Therapeutics (NASDAQ: PTCT) has agreed to acquire Emflaza, a treatment for Duchenne muscular dystrophy, from Marathon Pharmaceuticals for $140 million. The drug is the first in the US to be approved to treat Duchenne in patients five years and older. The sale comes after Marathon came under fire for its announced plan to charge $89,000 a year for Emflaza in the US, compared to a $1,000 price outside American borders.
In a separate deal, the UK’s Circassia Pharmaceuticals (LON: CIR) has secured the US rights to Tudorza and Duaklir, a pair of drugs used to treat chronic obstructive pulmonary disease, from AstraZeneca (LON: AZN). The deal is worth roughly $230 million, per Reuters. Tudorza was approved and launched in the US in 2012, while Duaklir should be submitted for US regulatory review in 2018.